Comment on Neiser et al. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int. J. Mol. Sci. 2016, 17, 1185.
Abstract
:To the Editor:
Conflicts of Interest
References
- Neiser, S.; Koskenkorva, T.S.; Schwarz, K.; Wilhelm, M.; Burckhardt, S. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int. J. Mol. Sci. 2016, 17, 1185. [Google Scholar] [CrossRef] [PubMed]
- Neiser, S.; Wilhelm, M.; Schwarz, K.; Funk, F.; Geisser, P.; Burckhardt, S. Assessment of dextran antigenicity of intravenous iron products by an immunodiffusion assay. Port. J. Nephrol. Hypertens. 2011, 25, 219–224. [Google Scholar]
- Crichton, R.R.; Danielson, B.G.; Geisser, P. Iron Therapy with Special Emphasis on Intravenous Administration, 4th ed.; UNI-MED: Bremen, Germany, 2008. [Google Scholar]
- Ring, J.; Valenta, R. Letter to the editor by Johannes Ring and Rudi Valenta on the article “Assessment of dextran antigenicity of intravenous iron products by an immunodiffusion assay”. Port. J. Nephrol. Hypertens. 2012, 26, 308–310. [Google Scholar]
- Neiser, S.; Wilhelm, M.; Schwarz, K.; Funk, F.; Geisser, P.; Burckhardt, S. Reply to the letter to the editor by Johannes Ring and Rudi Valenta on the article “Assessment of dextran antigenicity of intravenous iron products by an immunodiffusion assay”. Port. J. Nephrol. Hypertens. 2012, 26, 311–312. [Google Scholar]
- Szebeni, J.; Fishbane, S.; Hedenus, M.; Howaldt, S.; Locatelli, F.; Patni, S.; Rampton, D.; Weiss, G.; Folkersen, J. Hypersensitivity to intravenous iron: Classification, terminology, mechanisms and management. Br. J. Pharmacol. 2015, 172, 5025–5036. [Google Scholar] [CrossRef] [PubMed]
- Kreimeier, U.; Christ, F.; Kraft, D.; Lauterjung, L.; Niklas, M.; Peter, K.; Messmer, K. Anaphylaxis due to hydroxyethyl-starch-reactive antibodies. Lancet 1995, 346, 49–50. [Google Scholar] [CrossRef]
- LABEL: INJECTAFER-Ferric Carboxymaltose Injection. Available online: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=517b4a19-45b3-4286-9f6a-ced4e10447de (accessed on 14 September 2016).
- Kalra, P.A.; Bhandari, S. Safety of intravenous iron use in chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 2016, 25. [Google Scholar] [CrossRef] [PubMed]
© 2017 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Strom, C.C.; Andreasen, H.B. Comment on Neiser et al. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int. J. Mol. Sci. 2016, 17, 1185. Int. J. Mol. Sci. 2017, 18, 121. https://doi.org/10.3390/ijms18010121
Strom CC, Andreasen HB. Comment on Neiser et al. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int. J. Mol. Sci. 2016, 17, 1185. International Journal of Molecular Sciences. 2017; 18(1):121. https://doi.org/10.3390/ijms18010121
Chicago/Turabian StyleStrom, Claes C., and Hans B. Andreasen. 2017. "Comment on Neiser et al. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int. J. Mol. Sci. 2016, 17, 1185." International Journal of Molecular Sciences 18, no. 1: 121. https://doi.org/10.3390/ijms18010121